ES2160573T3 - Vectores pura estables y sus usos. - Google Patents

Vectores pura estables y sus usos.

Info

Publication number
ES2160573T3
ES2160573T3 ES92105887T ES92105887T ES2160573T3 ES 2160573 T3 ES2160573 T3 ES 2160573T3 ES 92105887 T ES92105887 T ES 92105887T ES 92105887 T ES92105887 T ES 92105887T ES 2160573 T3 ES2160573 T3 ES 2160573T3
Authority
ES
Spain
Prior art keywords
selection
chromosomic
maintenance
complementation
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92105887T
Other languages
English (en)
Inventor
Iii Robert Newton Brey
James Peter Fulginiti
Algis Anilionis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2160573T3 publication Critical patent/ES2160573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

LA INVENCION PERTENECE A UN SISTEMA DE COMPLEMENTACION PARA LA SELECCION Y MANTENIMIENTO DE GENES EXPRESADOS EN ANFITRIONES BACTERIANOS. LA INVENCION SUMINISTRA UNOS VECTORES ESTABLES QUE PUEDEN SELECCIONARSE Y MANTENERSE MEDIANTE LA COMPLEMENTACION DE MUTACIONES DE ELIMINACION CROMOSOMICA DE PURA (SINTETASA DE ADENILOSUCINATO), OBVIANDO EL USO DE GENES DE RESISTENCIA ANTIBIOTICA. EL SISTEMA ES UTIL EN LA PRODUCCION DE ORGANISMOS DURANTE LA FERMENTACION Y EN BACTERIAS VIVAS PARA VACUNAS, TALES COMO LA SALMONELLA TYPHI ATENUADA. ESTE SISTEMA PERMITE LA SELECCION DE INTEGRANTES CROMOSOMICOS Y LA SELECCION DE UN MANTENIMIENTO PLASMIDO ESTABLE EN LOS ANFITRIONES VACUNADOS SIN LA APLICACION DE PRESION DE SELECCION EXTERNA.
ES92105887T 1991-05-03 1992-04-06 Vectores pura estables y sus usos. Expired - Lifetime ES2160573T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69570691A 1991-05-03 1991-05-03

Publications (1)

Publication Number Publication Date
ES2160573T3 true ES2160573T3 (es) 2001-11-16

Family

ID=24794162

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92105887T Expired - Lifetime ES2160573T3 (es) 1991-05-03 1992-04-06 Vectores pura estables y sus usos.

Country Status (16)

Country Link
US (2) US5919663A (es)
EP (1) EP0512260B1 (es)
JP (1) JP3320095B2 (es)
KR (1) KR100242798B1 (es)
AT (1) ATE202800T1 (es)
AU (1) AU654347B2 (es)
CA (1) CA2067862C (es)
DE (1) DE69231907T2 (es)
DK (1) DK0512260T3 (es)
ES (1) ES2160573T3 (es)
FI (1) FI111013B (es)
GR (1) GR3036487T3 (es)
IL (1) IL101751A0 (es)
NO (1) NO314043B1 (es)
PT (1) PT512260E (es)
TW (1) TW201794B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
WO1998010074A2 (de) * 1996-09-04 1998-03-12 Basf Aktiengesellschaft Adenylosuccinat synthetase
EP0973865A2 (en) * 1997-04-11 2000-01-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
US6010705A (en) * 1997-04-11 2000-01-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
KR100427587B1 (ko) * 2001-01-12 2004-04-27 주식회사 바이오리더스 신규 ｄ-글루탐산 합성효소 유전자 ｄｎａ 및 이를 이용한 항생제 비의존성 벡터
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
AU2003210688A1 (en) * 2002-01-31 2003-09-02 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
EP2152883A4 (en) * 2007-05-10 2010-10-27 Univ Arizona RECOMBINANT BACTERIA WITH VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES-CODING ANTIGENES
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US20130266983A1 (en) * 2010-12-14 2013-10-10 The Regents Of The University Of California Creation of super-stable ColE1 plasmids by duplication of SL1-4 sequence and point mutations.
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
KR102006976B1 (ko) * 2019-02-26 2019-08-06 씨제이제일제당 주식회사 신규 프로모터 및 이를 이용한 퓨린 뉴클레오티드 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025118A1 (de) * 1979-08-18 1981-03-18 Riedlinger, Rainer, Dr.-Ing. Anordnung zur akustischen Wiedergabe von Signalen, die mittels eines rechten und eines linken Stereo-Kanals darstellbar sind
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
DK410783D0 (da) * 1982-09-16 1983-09-09 Benzon A Salfred Fremgangsmade til stabilisering af plasmider
EP0251579A3 (en) * 1986-06-24 1989-03-22 Enterovax Research Pty. Ltd. Non-antibiotic marker system
CA1340903C (fr) * 1986-08-05 2000-02-22 Transgene S.A. Procede de stabilisation d'un plasmide contenu dans une soche bacterienne et souche obtenue
JPS6427477A (en) * 1987-04-01 1989-01-30 Takeda Chemical Industries Ltd Dna and use thereof
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
JPH04504656A (ja) * 1989-03-31 1992-08-20 ワシントン ユニバーシティー ボルデテラワクチン
JP3367950B2 (ja) * 1990-12-18 2003-01-20 ザ ジェネラル ホスピタル コーポレーション 改良されたワクチン

Also Published As

Publication number Publication date
FI111013B (fi) 2003-05-15
AU1595992A (en) 1992-11-05
DE69231907D1 (de) 2001-08-09
GR3036487T3 (en) 2001-11-30
EP0512260A3 (en) 1993-07-28
AU654347B2 (en) 1994-11-03
US5919663A (en) 1999-07-06
PT512260E (pt) 2001-12-28
DK0512260T3 (da) 2001-09-17
JP3320095B2 (ja) 2002-09-03
FI921940A0 (fi) 1992-04-30
NO921729L (no) 1992-11-04
TW201794B (es) 1993-03-11
US5961983A (en) 1999-10-05
EP0512260A2 (en) 1992-11-11
KR100242798B1 (ko) 2000-02-01
JPH05192161A (ja) 1993-08-03
ATE202800T1 (de) 2001-07-15
NO921729D0 (no) 1992-04-30
NO314043B1 (no) 2003-01-20
KR920021701A (ko) 1992-12-18
CA2067862C (en) 2003-12-30
IL101751A0 (en) 1992-12-30
CA2067862A1 (en) 1992-11-04
DE69231907T2 (de) 2001-10-18
FI921940L (fi) 1992-11-04
EP0512260B1 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
ES2160573T3 (es) Vectores pura estables y sus usos.
McClung Isolation of Nocardia asteroides from soils
GB1097908A (en) A fermentation process for the production of l-threonine
GB1132624A (en) Improvements in or relating to fishing rods
ES2170057T3 (es) Utilizacion de los antibioticos ionoforos polieteres para limitar el crecimiento bacteriano en fermentacion alcoholica industrial.
Lortet Researches on the pathogenic microbes of the mud of the Dead Sea
IL67818A0 (en) Vaccines comprising ozone inactivated organisms and their production
WANG et al. Practice and exploration of high-quality development of residential training bases
Marziyeh Ansari et al. Isolation of atrazine degrading bacteria in semi-salinity medium
MUHAMMAD IN VITRO ASSESSMENT OF THE ANTIMICROBIAL PROPERTIES OF THE EXTRACTS OF SOME LOCAL MEDICINAL PLANTS ON AGENTS OF GASTROENTERITIS
HUANG Isolation and identification of several photosynthesis bacteria and their application in the culture of Tilapia sp
Lederberg PETER BENT BRIGHAM HOSPITAL
CAO et al. Isolation and identification of the cellulose-utilizing bacteria from the gut of apriona germati (Hope)
GB1366914A (en) Production and use of a methane oxidizing bacterial strain
WANG et al. The Developments of Microbial Resistance to Industrial Antiseptics and Disinfectants
WANG et al. Growth, siderophore production and outer membrane protein expression of Vibrio alginolyticus by iron regulation
GUO The Growth Characteristic of Antarctic Marine Bacterium BSw10005
HOK et al. The Use of Anesthesin in the Differentiation of Mycobacteria
Gratia Health Propaganda
JPS56121495A (en) Preparation of benzodiazepine derivative
Kim Disinfection by increased hydrostatic pressure.
Khanam et al. Phytochemical screening and antibacterial activity of
ES431205A1 (es) Un metodo de produccion del antibiotico fr-02a.
González-Rey Action of 5-hydroxytryptamine on growth of Raphanus sativus root
DAVIS JR Studies on the Nutrition of Arcella

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 512260

Country of ref document: ES